Healthcare Innovation Without Borders
･ Biotech
･ Medtech & Life science
･ Biotech Supporting Ecosystem
Founded in 2015, Apricot Capital is a leading investment firm deeply rooted in China's vibrant healthcare ecosystem. With a mission to nurture groundbreaking innovation and bridge the gap between China's burgeoning biotech sector and the global healthcare landscape. We specialize in incubating and scaling early- and growth- stage companies in innovative biotech, medtech & life science, and biotech supporting ecosystem poised to address critical unmet global clinical needs.
70+
Portfolio Companies
$12B+
Transaction Value
300+
Expert Advisors
Top20
Healthcare VC (2024)
Our Approach :
At Apricot Capital, we define success by our ability to see the trends before they emerge. Our investment philosophy is built on value creation through advanced incubation, with a strong focus on propelling Chinese enterprises onto the global stage.
By providing strategic support and fostering innovation, the firm has facilitated numerous international out- licensing deals. Notable successes include partnerships with leading multinational corporations such as Johnson & Johnson, AstraZeneca, BioNTech, Roche, and Novartis, with over 20 innovative drugs licensed out and total transaction values surpassing $12 billion USD.
By providing strategic support and fostering innovation, the firm has facilitated numerous international out- licensing deals. Notable successes include partnerships with leading multinational corporations such as Johnson & Johnson, AstraZeneca, BioNTech, Roche, and Novartis, with over 20 innovative drugs licensed out and total transaction values surpassing $12 billion USD.
Portfolio Companies :
·Biotech: Novel therapeutics addressing a wide range of diseases.
·Medtech & Life science: Cutting-edge medical equipment and tools, including high-end life science instruments.
·Biotech Supporting Ecosystem: Disruptive services supporting the healthcare ecosystem.
We primarily invest in early-stage and growth-stage companies, with a significant focus on Angel and Series A rounds, nurturing companies from their inception to maturity.
·Medtech & Life science: Cutting-edge medical equipment and tools, including high-end life science instruments.
·Biotech Supporting Ecosystem: Disruptive services supporting the healthcare ecosystem.
We primarily invest in early-stage and growth-stage companies, with a significant focus on Angel and Series A rounds, nurturing companies from their inception to maturity.